Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DTaP-IPV-HB-Hib vaccine
- Development stage
- Approved
- Lead developer
- Parent
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
The DTaP-IPV-HB-Hib vaccine is a hexavalent (6-in-1) combination vaccine designed to protect infants and young children against six serious diseases: diphtheria, tetanus, pertussis (whooping cough), polio (inactivated poliovirus), Haemophilus influenzae type b (Hib), and hepatitis B. The mechanism of action involves stimulating the immune system to produce antibodies against each of these pathogens using inactivated toxins or antigens from the respective bacteria or viruses. This results in active immunization that provides long-term protection. The primary indication is for routine childhood immunization starting at 6 weeks of age[1][3][5]. Vaxelis is a branded formulation developed by Sanofi Pasteur and Merck.
- Brand names
- Vaxelis
- Other names
- hexavalent combination vaccinediphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus B conjugate and hepatitis B vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)γδ TCR (T-cell receptor)Diphtheria toxinHBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on DTaP-IPV-HB-Hib vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DTaP-IPV-HB-Hib vaccine.